ME LD1687

MaineCare must reimburse pharmacists for prescribing, dispensing, and administering HIV prevention drugs (PrEP/PEP) by January 1, 2027, with pharmacists able to bill directly as the provider

Health insurance carriers must cover HIV prevention drugs prescribed by pharmacists, with no out-of-pocket costs for drugs rated A or B by the US Preventive Services Task Force

Carriers cannot impose prior authorization or step therapy requirements for HIV prevention drugs that meet USPSTF A or B ratings, and cannot prohibit pharmacists from prescribing these medications

Pharmacists may dispense up to 60 days of oral PrEP or one injectable dose without a prescription, provided the patient tests HIV-negative within 7 days and meets other safety requirements

Appropriates $192,824 total in FY 2026-27 ($44,264 General Fund, $146,951 federal, $1,609 other) for MaineCare reimbursement and technology implementation costs